Addiction Disorders Drugs Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Addiction Disorders Drugs Market is expected to grow from USD 21,296.38 Million in 2020 to USD 27,741.67 Million by the end of 2025.
2. The Global Addiction Disorders Drugs Market is expected to grow from EUR 18,673.07 Million in 2020 to EUR 24,324.42 Million by the end of 2025.
3. The Global Addiction Disorders Drugs Market is expected to grow from GBP 16,600.40 Million in 2020 to GBP 21,624.46 Million by the end of 2025.
4. The Global Addiction Disorders Drugs Market is expected to grow from JPY 2,272,863.39 Million in 2020 to JPY 2,960,739.16 Million by the end of 2025.
5. The Global Addiction Disorders Drugs Market is expected to grow from AUD 30,925.17 Million in 2020 to AUD 40,284.59 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Addiction Disorders Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Geography, the Addiction Disorders Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Addiction Disorders Drugs Market including Accord Healthcare, Alkermes PLC, Aurobindo Pharma Limited, BioCorRx Inc, Cipla Limited, Consern Pharma Limited, GlaxoSmithKline PLC, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Medtronic PLC, Novartis AG, Opiant Technologies Pvt. Ltd., OraSure Technologies, Inc, Perrigo Company PLC, Pfizer, Inc, PSYCHEMEDICS CORPORATION, Purdue Pharma L.P., Reckitt Benckiser Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Ltd, and Teva Pharmaceutical Industries, Ltd.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Addiction Disorders Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Addiction Disorders Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Addiction Disorders Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Addiction Disorders Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Addiction Disorders Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Addiction Disorders Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Addiction Disorders Drugs Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Addiction Disorders Drugs Market is expected to grow from USD 21,296.38 Million in 2020 to USD 27,741.67 Million by the end of 2025.
2. The Global Addiction Disorders Drugs Market is expected to grow from EUR 18,673.07 Million in 2020 to EUR 24,324.42 Million by the end of 2025.
3. The Global Addiction Disorders Drugs Market is expected to grow from GBP 16,600.40 Million in 2020 to GBP 21,624.46 Million by the end of 2025.
4. The Global Addiction Disorders Drugs Market is expected to grow from JPY 2,272,863.39 Million in 2020 to JPY 2,960,739.16 Million by the end of 2025.
5. The Global Addiction Disorders Drugs Market is expected to grow from AUD 30,925.17 Million in 2020 to AUD 40,284.59 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Addiction Disorders Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Geography, the Addiction Disorders Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Addiction Disorders Drugs Market including Accord Healthcare, Alkermes PLC, Aurobindo Pharma Limited, BioCorRx Inc, Cipla Limited, Consern Pharma Limited, GlaxoSmithKline PLC, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Medtronic PLC, Novartis AG, Opiant Technologies Pvt. Ltd., OraSure Technologies, Inc, Perrigo Company PLC, Pfizer, Inc, PSYCHEMEDICS CORPORATION, Purdue Pharma L.P., Reckitt Benckiser Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Ltd, and Teva Pharmaceutical Industries, Ltd.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Addiction Disorders Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Addiction Disorders Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Addiction Disorders Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Addiction Disorders Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Addiction Disorders Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Addiction Disorders Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Addiction Disorders Drugs Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Geography Outlook
3.4. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalences of addictive substances such as alcohol, tobacco, and drugs among all age groups
5.1.1.2. Government intervention and encouragement to curb addiction disorders
5.1.1.3. Rising number of approved medicines and the increased use of nicotine with other stimulants
5.1.2. Restraints
5.1.2.1. Limited awareness about addiction treatment products in developing countries
5.1.2.2. Multiple side-effects associated with the use of methadone
5.1.3. Opportunities
5.1.3.1. Availability of innovative drugs in the form of pills, sublingual films, and implants
5.1.4. Challenges
5.1.4.1. Legal obligations for addiction treatment products
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. AMERICAS ADDICTION DISORDERS DRUGS MARKET
6.1. Introduction
6.2. Argentina
6.3. Brazil
6.4. Canada
6.5. Mexico
6.6. United States
7. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET
7.1. Introduction
7.2. Australia
7.3. China
7.4. India
7.5. Indonesia
7.6. Japan
7.7. Malaysia
7.8. Philippines
7.9. South Korea
7.10. Thailand
8. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET
8.1. Introduction
8.2. France
8.3. Germany
8.4. Italy
8.5. Netherlands
8.6. Qatar
8.7. Russia
8.8. Saudi Arabia
8.9. South Africa
8.10. Spain
8.11. United Arab Emirates
8.12. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. FPNV Positioning Matrix
9.1.1. Quadrants
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis
9.4. Competitor SWOT Analysis
9.5. Competitive Scenario
9.5.1. Merger & Acquisition
9.5.2. Agreement, Collaboration, & Partnership
9.5.3. New Product Launch & Enhancement
9.5.4. Investment & Funding
9.5.5. Award, Recognition, & Expansion
10. COMPANY USABILITY PROFILES
10.1. Accord Healthcare
10.2. Alkermes PLC
10.3. Aurobindo Pharma Limited
10.4. BioCorRx Inc
10.5. Cipla Limited
10.6. Consern Pharma Limited
10.7. GlaxoSmithKline PLC
10.8. Insys Therapeutics
10.9. Mallinckrodt Pharmaceuticals
10.10. Medtronic PLC
10.11. Novartis AG
10.12. Opiant Technologies Pvt. Ltd.
10.13. OraSure Technologies, Inc
10.14. Perrigo Company PLC
10.15. Pfizer, Inc
10.16. PSYCHEMEDICS CORPORATION
10.17. Purdue Pharma L.P.
10.18. Reckitt Benckiser Pharmaceuticals, Inc.
10.19. Sun Pharmaceutical Industries Limited
10.20. Takeda Pharmaceutical Company Ltd
10.21. Teva Pharmaceutical Industries, Ltd
11. APPENDIX
11.1. Discussion Guide
11.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Geography Outlook
3.4. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalences of addictive substances such as alcohol, tobacco, and drugs among all age groups
5.1.1.2. Government intervention and encouragement to curb addiction disorders
5.1.1.3. Rising number of approved medicines and the increased use of nicotine with other stimulants
5.1.2. Restraints
5.1.2.1. Limited awareness about addiction treatment products in developing countries
5.1.2.2. Multiple side-effects associated with the use of methadone
5.1.3. Opportunities
5.1.3.1. Availability of innovative drugs in the form of pills, sublingual films, and implants
5.1.4. Challenges
5.1.4.1. Legal obligations for addiction treatment products
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. AMERICAS ADDICTION DISORDERS DRUGS MARKET
6.1. Introduction
6.2. Argentina
6.3. Brazil
6.4. Canada
6.5. Mexico
6.6. United States
7. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET
7.1. Introduction
7.2. Australia
7.3. China
7.4. India
7.5. Indonesia
7.6. Japan
7.7. Malaysia
7.8. Philippines
7.9. South Korea
7.10. Thailand
8. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET
8.1. Introduction
8.2. France
8.3. Germany
8.4. Italy
8.5. Netherlands
8.6. Qatar
8.7. Russia
8.8. Saudi Arabia
8.9. South Africa
8.10. Spain
8.11. United Arab Emirates
8.12. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. FPNV Positioning Matrix
9.1.1. Quadrants
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis
9.4. Competitor SWOT Analysis
9.5. Competitive Scenario
9.5.1. Merger & Acquisition
9.5.2. Agreement, Collaboration, & Partnership
9.5.3. New Product Launch & Enhancement
9.5.4. Investment & Funding
9.5.5. Award, Recognition, & Expansion
10. COMPANY USABILITY PROFILES
10.1. Accord Healthcare
10.2. Alkermes PLC
10.3. Aurobindo Pharma Limited
10.4. BioCorRx Inc
10.5. Cipla Limited
10.6. Consern Pharma Limited
10.7. GlaxoSmithKline PLC
10.8. Insys Therapeutics
10.9. Mallinckrodt Pharmaceuticals
10.10. Medtronic PLC
10.11. Novartis AG
10.12. Opiant Technologies Pvt. Ltd.
10.13. OraSure Technologies, Inc
10.14. Perrigo Company PLC
10.15. Pfizer, Inc
10.16. PSYCHEMEDICS CORPORATION
10.17. Purdue Pharma L.P.
10.18. Reckitt Benckiser Pharmaceuticals, Inc.
10.19. Sun Pharmaceutical Industries Limited
10.20. Takeda Pharmaceutical Company Ltd
10.21. Teva Pharmaceutical Industries, Ltd
11. APPENDIX
11.1. Discussion Guide
11.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET: SCORES
TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET: BUSINESS STRATEGY
TABLE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RANKING
TABLE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET: MERGER & ACQUISITION
TABLE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET: SCORES
TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET: BUSINESS STRATEGY
TABLE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RANKING
TABLE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET: MERGER & ACQUISITION
TABLE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET: MARKET DYNAMICS
FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 11. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 12. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 14. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 15. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 16. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 17. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 18. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 20. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 22. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 23. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 24. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. INDONESIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MALAYSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. PHILIPPINES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. THAILAND ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 34. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. QATAR ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GLOBAL ADDICTION DISORDERS DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 46. GLOBAL ADDICTION DISORDERS DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ADDICTION DISORDERS DRUGS MARKET, BY TYPE
FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET: MARKET DYNAMICS
FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 11. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 12. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 14. ARGENTINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 15. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 16. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 17. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 18. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 20. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 22. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 23. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 24. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. INDONESIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MALAYSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. PHILIPPINES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. THAILAND ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 34. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. NETHERLANDS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. QATAR ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. SAUDI ARABIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. SOUTH AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. UNITED ARAB EMIRATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GLOBAL ADDICTION DISORDERS DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 46. GLOBAL ADDICTION DISORDERS DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ADDICTION DISORDERS DRUGS MARKET, BY TYPE
